Oct 25 (Reuters) - Boston Scientific's BSX.N quarterly results on Thursday are likely to show the benefits of a rebound in elective procedures and help ease fears that the medical device maker could ...

Boston Scientific has put forward pivotal clinical data from a head-to-head trial showing its pulsed field ablation approach for treating an irregular heartbeat can operate on par with traditional ...

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

Not surprisingly, Boston Scientific saw muted performance in the fourth quarter thanks to the resurgence in COVID-19 viral transmission, and we’re holding steady on our fair value estimate. Unlike ...

Oct 25 (Reuters) - Boston Scientific's (BSX.N), opens new tab quarterly results on Thursday are likely to show the benefits of a rebound in elective procedures and help ease fears that the medical ...

Narrow-moat Boston Scientific got off to a fast start in the first quarter, and we plan to slightly raise our fair value estimate after incorporating a quicker resumption of procedure volume, ...

Boston Scientific ($BSX) announced an update on their ongoing clinical study. Study OverviewThis global Boston Scientific trial, officially titled ...

A rebounding volume of medical procedures fueled a strong first quarter for Boston Scientific Corp., which topped market expectations for both sales and profits. The company, with significant ...

Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX ...